APLN and early-onset autosomal dominant Alzheimer disease: Therefore, apelin derivatives offer a viable therapeutic option for the treatment of these chronic progressive neurological conditions [418,425,433,434,435] such as Parkinson’s disease [436,437], Huntington’s disease [430], Alzheimer’s disease [414], and ALS.